Advanced

Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model

Odenholt, Inga LU ; Lowdin, E; Gustafsson, I and Cars, O (2002) In Antimicrobial Agents and Chemotherapy 46(6). p.2046-2048
Abstract
The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB... (More)
The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB strains at the lower dose was likely caused by the emergence of preexisting resistant subpopulations. Thus, the present study indicates that the presently used 400-mg dose seems to have an advantage over the lower dose in that the risk for selection of resistant subpopuIations is minimized. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Antimicrobial Agents and Chemotherapy
volume
46
issue
6
pages
2046 - 2048
publisher
American Society for Microbiology
external identifiers
  • pmid:12019138
  • wos:000175662800073
  • scopus:0036090592
ISSN
1098-6596
DOI
10.1128/AAC.46.6.2046-2048.2002
language
English
LU publication?
yes
id
bb2b0f2e-aa44-4857-a716-70ac74a9f6df (old id 893368)
date added to LUP
2008-01-23 22:15:24
date last changed
2017-01-01 07:23:10
@article{bb2b0f2e-aa44-4857-a716-70ac74a9f6df,
  abstract     = {The aim of the present study was to investigate the pharmacodynamics of moxifloxacin against strains of Streptococcus pyogenes with different susceptibilities to erythromycin by using an in vitro kinetic model simulating human pharmacokinetics of moxifloxacin at oral doses of 400 and 200 mg, respectively. When the different strains of S. pyogenes were exposed to the higher dose, the number of bacteria was reduced below the detection limit after 12 h and no regrowth was noted during the following 12 h. At the lower dose there was regrowth of the strains with constitutive and inducible erythromycin resistance of the MLSB phenotype. Replication assays of the regrowing bacteria indicated that the failure of moxifloxacin to kill the MLSB strains at the lower dose was likely caused by the emergence of preexisting resistant subpopulations. Thus, the present study indicates that the presently used 400-mg dose seems to have an advantage over the lower dose in that the risk for selection of resistant subpopuIations is minimized.},
  author       = {Odenholt, Inga and Lowdin, E and Gustafsson, I and Cars, O},
  issn         = {1098-6596},
  language     = {eng},
  number       = {6},
  pages        = {2046--2048},
  publisher    = {American Society for Microbiology},
  series       = {Antimicrobial Agents and Chemotherapy},
  title        = {Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model},
  url          = {http://dx.doi.org/10.1128/AAC.46.6.2046-2048.2002},
  volume       = {46},
  year         = {2002},
}